4121 results about "Mesenchymal stem cell" patented technology

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.

Compositions and methods for promoting mesenchymal stem cell expansion while maintaining a pluripotent phenotype are disclosed. Serum-free cell culture systems and kits and methods of use for mesenchymal stem cell expansion are provided. Methods also comprise the use of the expanded mesenchymal stem cells to treat various disorders or diseases, particularly those of the cardiovascular system, bone, or cartilage.

Methods of modifying stem cells, in particular mesenchymal stem cells, using electric or electromagnetic fields. In one embodiment, the present invention provides methods of modulating a mesenchymal stem cell activity, the method comprising administering electric stimulation to mesenchymal stem cells in vitro. In another embodiment, the present invention provides methods for the treatment of a human or other mammal subject in need thereof, comprising providing an in vitro culture comprising mesenchymal stem cells, administering an electric stimulation to the in vitro culture, and implanting the mesenchymal stem cells into the mammal subject. In another embodiment, the present invention provides methods for the treatment of a human or other mammal subject, the method comprising implanting mesenchymal stem cells into the mammal subject, and administering an electric stimulation to the mesenchymal stem cells in situ. The present invention also comprises compositions comprising mesenchymal stem cells treated with electric stimulation.

Provided are fibrin or silk matrices comprising an oxygen carrier, and matrices, which comprise an oxygen carrier and mesenchymal stem cells. Also provided are methods of generating and using same for ex vivo or in vivo tissue regeneration and/or repair such as for treating a non-union bone fracture and a condition requiring spinal fusion.

Methods of modifying stem cells and compositions of modified stem cells, in particular mesenchymal stem cells, using electric or electromagnetic fields. In various embodiments, the present invention's methods are for the treatment of a human or other mammal subject in need thereof, comprising providing an in vitro culture comprising mesenchymal stem cells, administering an electric stimulation to the in vitro culture, and implanting the mesenchymal stem cells into the subject. Methods also include treatment of a human or other mammal subject, comprising implanting mesenchymal stem cells into the subject, and administering an electric stimulation to the mesenchymal stem cells in situ. Other embodiments include methods of administering electric stimulation in conjunction with growth factors to stem cells.

The invention discloses a culture medium for culturing mesenchymal stem cells. The culture medium comprises improved minimum medium IMDM, cell growth factor combination, insulin, trace elements, lipid substances, vitamin substances, hormone substances, protein molecules, amino acid substances and other compounds. The culture medium provided by the invention does not contain serum or plasma (comprising animal or human serum or plasma), thus, when the system is used for culturing the mesenchymal stem cells, zoonosis caused by the animal serum or plasma in the cell therapy process can be avoided, and the risk of human immunity reaction which is possibly caused in the cell therapy process can be avoided. The culture medium has specific chemical constituent, thus the possibility of different cultured mesenchymal stem cell properties caused by the difference of culture systems can be avoided. The culture medium is not only suitable for culturing the mesenchymal stem cells of human marrow and umbilical cord resources but also suitable for culturing the mesenchymal stem cells of other tissues or other animals, and has the advantage of wide application range.

The invention generally provides compositions and methods for promoting and enhancing wound closure and healing. Specifically, the invention provides a biologic composition which comprises a support layer which serves as transport scaffold, for example made of gelatin, which is coated or impregnated with a bio-adhesive molecule such as rose bengal or glyceraldehyde. The composition can also comprise an artificial or biological matrix, optionally processed (i.e. cleaned and coated with extracellular matrix proteins) to enhance cell attachment and survival. The composition can further comprise a monolayer of epithelial, endothelial cells or mesenchymal cells. The invention provides methods for using the compositions for treating wounds due to disease, trauma or surgery. Specific methods for treating ocular wounds are provided.

Invention embodiments described herein include methods and devices for stimulating mesenchymal stem cells in a stem cell source to differentiate into osteoblasts capable of forming bone. Devices and methods described include exposing a stem cell source, such as bone marrow aspirate, adipose tissue and/or purified allogenic stem cells, to an active agent, in a manner effective to form activated stem cells.

Provided are novel methods and compositions for the diagnosis, prognosis and treatment of leiomyomas, in particular uterine leiomyoma (UL). In addition, methods of identifying anti-tumor agents are described. Furthermore, novel methods and compositions are provided for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of obesity are disclosed.

Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

The invention relates to the field of biology, and discloses a serum-free culture medium which essentially comprises an IMDM (Iscove Modified Dulbecco Medium), L-glutamine, sodium bicarbonate, Hepes, recombinant human insulin, recombinant human transferrin, recombinant human albumin, 2-mercaptoethanol, protocatechuic acid, lipid, amino acid, vitamins, trace elements, Pluronic F-68, hydrocortisone, vitamin C, bonding amine or recombinant human fibronectin, progesterone, putrescine, heparin, serotonin, epidermal growth factors (EGFs), b-fibroblast growth factors (FGF), platelet derive growth factor (PDGF)-BB and insulin-like growth factor (IGF)-I. The serum-free culture medium is clear in chemical components, free from animal sources and serum and safe and ideal in cell cultivation and avoids the doped animal components and unstable batches, and the results of the cultured mesenchymal stem cells show that the total cellular score, the cell phenotype and the secretory cell factors are normal, so that the serum-free culture medium has good industrial application prospect.

Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

The present application discloses methods for repairing hyaline cartilage defects. The methods comprise a combination of introducing autologous bone mesenchymal stem cells to a joint, and applying to the joint a membrane comprising a polyester entangled with a polysaccharide. In some aspects, the bone mesenchymal stem cells are mesenchymal stem cells originating in bone underlying the joint. In these aspects, contact between the joint and the mesenchymal stem cells can be effected by introducing apertures through the bone using standard surgical techniques such as microfracture, abrasion, or drilling. Cartilage which forms in response to application of these methods is hyaline cartilage rather than fibrocartilage.

Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk protein, Dickkopf-2 (Dkk-2), acts to stimulate bone formation independently of Wnt proteins which may be inhibited and/or antagonized by Dkk-2. Dkk-2 displayed enhanced specific targeting ability and enhanced biological activity in stimulating or enhancing mineralization. Dkk-2 also played a role in the differentiation and self-renewal of hematopoietic stem cells and mesenchymal stem cells, particularly in osteoblastogenesis and osteoclastogenesis.

The invention is directed to a device and method to prevent migration of Human Mesenchymal Stem Cells (hMSCs) from a delivery site while allowing communication between the stem cells and native cardiomyocytes. The device is characterized by scaffold pore size, fiber diameter and biomaterial selection. The invention includes a two part polyurethane scaffold that prevents migration of stem cells, allows gap junction formation through pores and is packaged for minimally invasive delivery.

The invention relates to a method for preparing human umbilical cord mesenchymal stem cells, which comprises the steps of collection, transportation, handover, separation, freezing, recovering, primary culture and subculture of umbilical cords. The method has simple process, ensures low production cost, good freezing effect, little cell damage, low toxic side effect and no harm to human body and reduces the residual of the freezing protection liquid in the recovered cells of tissue blocks; and the prepared mesenchymal stem cells can be applied to the clinical treatment of various diseases.

The present invention relates to a method and composition for the cryopreservation of adipose tissue with the intention to use this tissue in the culturing of stem and/or progenitor cells. The method uses a specific cryoprotection medium to prevent damage of the original tissue during the cryopreservation while still maintaining a high viability of the stem and/or progenitor cells obtained from the cryopreserved adipose tissue. Furthermore the cryoprotection medium of the present invention does not contain any kind of xenogeneic sera, a critical factor since it is the intention of that the cryopreserved tissue is used for obtaining stem and/or progenitor cells that can be used in medicine. The cryoprotection medium is characterized in that it is a solution of physiological water comprising glycerol and sucrose and/or trehalose and optionally serum albumin.

The invention relates to a human mesenchymal stem cell culture medium. According to the culture medium, the basal culture medium comprises the following components based on the final concentration: 1-2g/L of human serum albumin, 5-10mg/L of transferring, 2-8mg/L of fibronectin, 1-4mg/L of laminin, 50g/L of Fe(NO3)3.9H2O, 417g/L of FeSO4.7H2O, 1-3mu g/L of estradiol, 2-5mu g/L of testosterone, 1-3mu g/L of progesterone, 39.25-117.74 mu g/L of dexamethasone, 5-10mg/L of insulin, 376.36mg/L of riboflavin, 80.96-242.87mg/L of coenzyme A, 4.41-6.17mg/L of butanediamine, 1-2mg/L of taurine, 0.61-1.85mg/L of aminoethanol, 8.81-26.42mg/L of pyruvic acid, 3.78-7.56mu g/L of sodium selenate, 292.3-584.6mg/L of L-glutamine, 2-8mu g/L of vascular endothelial growth factor, 4-10mu g/L of epidermal growth factor, 4-10mu g/L of basic fibroblast growth factor, 1-5mu g/L of leukaemia inhibitory factor, 1-5mu g/L of insulin-like growth factor-I and 2-8mu g/L of stem cell factor. The culture medium does not contain the animal serum, the potential animal endogenous endotoxin or virus of the animal serum is eliminated, and the culture medium is conveniently applied to clinics.

The invention discloses a human fat mesenchymal stem cell extract and lyophilized powder and applications thereof. The human fat mesenchymal stem cell extract is prepared by the steps: collecting subcultured P3-P30 generations of human fat mesenchymal stem cells, culturing with cell growth liquid until 80% of cells are fused, removing culture liquid, washing the cells with a phosphate buffer solution for three times, adding into a serum-free culture solution, continuously culturing for 72 hours, collecting the serum-free culture solution, digesting uncollected cells with a digestion solution, crushing the cells with an ultrasonic crushing device, centrifuging, and then collecting supernatant; and mixing the collected serum-free culture solution and the collected supernatant, filtering, collecting filtrate, concentrating, and sterilizing. The human fat mesenchymal stem cell extract and the lyophilized powder thereof have multiple biological activities, can be used for preparing wound healing or cell repair medicaments and other biopharmaceutical products, and can also be used for preparing whitening products or skin anti-wrinkle products and other fine chemical products.

The current invention provides a method for mobilising endothelial progenitor cells (EPC) and/or mesenchymal stem cells (MSC) in a patient, wherein the method comprises the steps of (i) administering a vascular endothelial growth factor receptor (VEGFR) agonist to the patient; and (ii) administering an antagonist of CXCR4 to the patient. Also provided are uses of EPC and MSC harvested using the methods of the invention.

The invention provides compositions comprising mesenchymal stem cell (MSC) derived exosomes, and methods of their use in subjects having certain lung diseases including inflammatory lung disease.